 TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that TACROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
| Descriptor ID |
D058570
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
| Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- Mechanistic Target of Rapamycin Protein
- TOR Kinases
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in UAMS Profiles by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 1 | 1 | 2 | | 2022 | 0 | 2 | 2 | | 2021 | 2 | 0 | 2 | | 2020 | 2 | 3 | 5 | | 2019 | 2 | 2 | 4 | | 2018 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2016 | 3 | 3 | 6 | | 2015 | 1 | 4 | 5 | | 2014 | 2 | 2 | 4 | | 2013 | 2 | 2 | 4 | | 2012 | 1 | 3 | 4 | | 2011 | 1 | 1 | 2 | | 2010 | 3 | 6 | 9 | | 2008 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles over the past ten years.
-
Rossetti CL, Alves BL, Pe?anha FLM, Franco AT, Nos? V, Carneiro EM, Lew J, Bernal-Mizrachi E, Werneck-de-Castro JP. Defining the In Vivo Role of mTORC1 in Thyrocytes by Studying the TSC2 Conditional Knockout Mouse Model. Thyroid. 2024 Aug; 34(8):1047-1057.
-
Khalil MI, Ali MM, Holail J, Houssein M. Growth or death? Control of cell destiny by mTOR and autophagy pathways. Prog Biophys Mol Biol. 2023 Dec; 185:39-55.
-
Roy T, Banang-Mbeumi S, Boateng ST, Ruiz EM, Chamcheu RN, Kang L, King JA, Walker AL, Nagalo BM, Kousoulas KG, Esnault S, Huang S, Chamcheu JC. Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation. Front Immunol. 2022; 13:1075804.
-
Kreher MA, Noland MMB, Konda S, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. J Am Acad Dermatol. 2023 Mar; 88(3):521-530.
-
Calder PC, Deutz NEP. Measuring muscle protein synthesis in humans and the influence of nutritional state. Clin Sci (Lond). 2022 10 14; 136(19):1425-1431.
-
Castillo-Castrejon M, Yang IV, Davidson EJ, Borengasser SJ, Jambal P, Westcott J, Kemp JF, Garces A, Ali SA, Saleem S, Goldenberg RL, Figueroa L, Hambidge KM, Krebs NF, Powell TL. Preconceptional Lipid-Based Nutrient Supplementation in 2 Low-Resource Countries Results in Distinctly Different IGF-1/mTOR Placental Responses. J Nutr. 2021 03 11; 151(3):556-569.
-
Wang W, Li J, Tan J, Wang M, Yang J, Zhang ZM, Li C, Basnakian AG, Tang HW, Perrimon N, Zhou Q. Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response. Nat Commun. 2021 01 20; 12(1):476.
-
Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman VS, Hill RA, Kousoulas KG, Nagalo BM, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem. 2021 02; 107:104595.
-
Fang B, Kannan A, Zhao S, Nguyen QH, Ejadi S, Yamamoto M, Camilo Barreto J, Zhao H, Gao L. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Sci Rep. 2020 06 01; 10(1):8867.
-
Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight. 2020 05 07; 5(9).
-
Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K, McKenney JK. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020 05; 44(5):571-581.
-
Von Walden F, Rea M, Mobley CB, Fondufe-Mittendorf Y, McCarthy JJ, Peterson CA, Murach KA. The myonuclear DNA methylome in response to an acute hypertrophic stimulus. Epigenetics. 2020 11; 15(11):1151-1162.
-
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2020 02; 156(2):301-307.
-
Figueiredo VC, Dungan CM, Peterson CA, McCarthy JJ. On the appropriateness of antibody selection to estimate mTORC1 activity. Acta Physiol (Oxf). 2020 02; 228(2):e13354.
-
Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 08 13; 129(10):4451-4463.
-
de Lima-Seolin BG, Nemec-Bakk A, Forsyth H, Kirk S, da Rosa Araujo AS, Schenkel PC, Bell?-Klein A, Khaper N. Bucindolol Modulates Cardiac Remodeling by Attenuating Oxidative Stress in H9c2 Cardiac Cells Exposed to Norepinephrine. Oxid Med Cell Longev. 2019; 2019:6325424.
-
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019 03 04; 129(4):1641-1653.
-
Fang B, Kannan A, Guo T, Gao L. Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis. Int J Biol Sci. 2018; 14(10):1221-1231.
-
Lutkewitte AJ, Schweitzer GG, Kennon-McGill S, Clemens MM, James LP, Jaeschke H, Finck BN, McGill MR. Lipin deactivation after acetaminophen overdose causes phosphatidic acid accumulation in liver and plasma in mice and humans and enhances liver regeneration. Food Chem Toxicol. 2018 May; 115:273-283.
-
Stuart CA, Lee ML, South MA, Howell MEA, Stone MH. Muscle hypertrophy in prediabetic men after 16 wk of resistance training. J Appl Physiol (1985). 2017 Oct 01; 123(4):894-901.
-
Borack MS, Reidy PT, Husaini SH, Markofski MM, Deer RR, Richison AB, Lambert BS, Cope MB, Mukherjea R, Jennings K, Volpi E, Rasmussen BB. Soy-Dairy Protein Blend or Whey Protein Isolate Ingestion Induces Similar Postexercise Muscle Mechanistic Target of Rapamycin Complex 1 Signaling and Protein Synthesis Responses in Older Men. J Nutr. 2016 Dec; 146(12):2468-2475.
-
Ogunbileje JO, Porter C, Herndon DN, Chao T, Abdelrahman DR, Papadimitriou A, Chondronikola M, Zimmers TA, Reidy PT, Rasmussen BB, Sidossis LS. Hypermetabolism and hypercatabolism of skeletal muscle accompany mitochondrial stress following severe burn trauma. Am J Physiol Endocrinol Metab. 2016 08 01; 311(2):E436-48.
-
Ding Z, Liu S, Wang X, Mathur P, Dai Y, Theus S, Deng X, Fan Y, Mehta JL. Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis. Antioxid Redox Signal. 2016 12 20; 25(18):997-1008.
-
Church DD, Schwarz NA, Spillane MB, McKinley-Barnard SK, Andre TL, Ramirez AJ, Willoughby DS. l-Leucine Increases Skeletal Muscle IGF-1 but Does Not Differentially Increase Akt/mTORC1 Signaling and Serum IGF-1 Compared to Ursolic Acid in Response to Resistance Exercise in Resistance-Trained Men. J Am Coll Nutr. 2016 Sep-Oct; 35(7):627-638.
-
Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonz?lez-Mart?n A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016 Jul; 142(1):62-69.
-
Kannan A, Lin Z, Shao Q, Zhao S, Fang B, Moreno MA, Vural E, Stack BC, Suen JY, Kannan K, Gao L. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. Oncotarget. 2016 Feb 09; 7(6):6576-92.
-
Kaushal GP, Shah SV. Autophagy in acute kidney injury. Kidney Int. 2016 Apr; 89(4):779-91.
-
Gonzalez AM, Hoffman JR, Jajtner AR, Townsend JR, Boone CH, Beyer KS, Baker KM, Wells AJ, Church DD, Mangine GT, Oliveira LP, Moon JR, Fukuda DH, Stout JR. Protein supplementation does not alter intramuscular anabolic signaling or endocrine response after resistance exercise in trained men. Nutr Res. 2015 Nov; 35(11):990-1000.
-
Samanta D. Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma. Indian J Dermatol Venereol Leprol. 2015 Sep-Oct; 81(5):540-1.
-
Sereno J, Vala H, Nunes S, Rocha-Pereira P, Carvalho E, Alves R, Teixeira F, Reis F. Cyclosporine A-induced nephrotoxicity is ameliorated by dose reduction and conversion to sirolimus in the rat. J Physiol Pharmacol. 2015 Apr; 66(2):285-99.
-
Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29.
-
Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, Schulze JM, Barnes D, McCullough AJ, Engelen MP, Deutz NE, Dasarathy S. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015 Jun; 61(6):2018-29.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|